echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ascletis Pharma Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

    Ascletis Pharma Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of February 13, according to the Financial Associated Press, Ascletis Pharmaceuticals announced that it has submitted a marketing authorization application for ritonavir (100 mg film-coated tablet) to Germany, France, Ireland and the United Kingdom through its European agents


    At the same time, Ascletis continues to negotiate cooperation with domestic and international companies, including large multinational pharmaceutical companies, on the commercial supply of ritonavir in China and globally


    Oral ritonavir tablet is one of the pharmacokinetic enhancers of various oral antiviral drugs against viral protease and one of the components of oral antiviral drug Paxlovid (combination packaging of nematevir tablets + ritonavir tablets)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.